Apellis Pharmaceuticals Announces 18-Month Results of Phase 2 Study (FILLY) of APL-2 in Geographic Atrophy
February 23, 2018
Data supports biologic activity of APL-2 in reducing the growth rate of geographic atrophy CRESTWOOD, Ky. and CAMBRIDGE, Mass., Feb. 22, 2018 – Apellis Pharmaceuticals,